Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 154

1.

Activation of LXRβ inhibits tumor respiration and is synthetically lethal with Bcl-xL inhibition.

Nguyen TTT, Ishida CT, Shang E, Shu C, Torrini C, Zhang Y, Bianchetti E, Sanchez-Quintero MJ, Kleiner G, Quinzii CM, Westhoff MA, Karpel-Massler G, Canoll P, Siegelin MD.

EMBO Mol Med. 2019 Aug 29:e10769. doi: 10.15252/emmm.201910769. [Epub ahead of print]

2.

Extent of resection and survival for oligodendroglioma: a U.S. population-based study.

Kinslow CJ, Garton ALA, Rae AI, Marcus LP, Adams CM, McKhann GM, Sisti MB, Connolly ES, Bruce JN, Neugut AI, Sonabend AM, Canoll P, Cheng SK, Wang TJC.

J Neurooncol. 2019 Aug 12. doi: 10.1007/s11060-019-03261-5. [Epub ahead of print]

PMID:
31407129
3.

Correction to: Sequencing and curation strategies for identifying candidate glioblastoma treatments.

Frank MO, Koyama T, Rhrissorrakrai K, Robine N, Utro F, Emde AK, Chen BJ, Arora K, Shah M, Geiger H, Felice V, Dikoglu E, Rahman S, Fang X, Vacic V, Bergmann EA, Moore Vogel JL, Reeves C, Khaira D, Calabro A, Kim D, Lamendola-Essel MF, Esteves C, Agius P, Stolte C, Boockvar J, Demopoulos A, Placantonakis DG, Golfinos JG, Brennan C, Bruce J, Lassman AB, Canoll P, Grommes C, Daras M, Diamond E, Omuro A, Pentsova E, Orange DE, Harvey SJ, Posner JB, Michelini VV, Jobanputra V, Zody MC, Kelly J, Parida L, Wrzeszczynski KO, Royyuru AK, Darnell RB.

BMC Med Genomics. 2019 Aug 2;12(1):114. doi: 10.1186/s12920-019-0563-y.

4.

Validation of an effective implantable pump-infusion system for chronic convection-enhanced delivery of intracerebral topotecan in a large animal model.

D'Amico RS, Neira JA, Yun J, Alexiades NG, Banu M, Englander ZK, Kennedy BC, Ung TH, Rothrock RJ, Romanov A, Guo X, Zhao B, Sonabend AM, Canoll P, Bruce JN.

J Neurosurg. 2019 Aug 2:1-10. doi: 10.3171/2019.3.JNS1963. [Epub ahead of print]

PMID:
31374547
5.

ENvironmental Dynamics Underlying Responsive Extreme Survivors (ENDURES) of Glioblastoma: A Multidisciplinary Team-based, Multifactorial Analytical Approach.

Johnston SK, Whitmire P, Massey SC, Kumthekar P, Porter AB, Raghunand N, Gonzalez-Cuyar LF, Mrugala MM, Hawkins-Daarud A, Jackson PR, Hu LS, Sarkaria JN, Wang L, Gatenby RA, Egan KM, Canoll P, Swanson KR; ENDURES consortium.

Am J Clin Oncol. 2019 Aug;42(8):655-661. doi: 10.1097/COC.0000000000000564.

PMID:
31343422
6.

Myosin IIA suppresses glioblastoma development in a mechanically sensitive manner.

Picariello HS, Kenchappa RS, Rai V, Crish JF, Dovas A, Pogoda K, McMahon M, Bell ES, Chandrasekharan U, Luu A, West R, Lammerding J, Canoll P, Odde DJ, Janmey PA, Egelhoff T, Rosenfeld SS.

Proc Natl Acad Sci U S A. 2019 Jul 30;116(31):15550-15559. doi: 10.1073/pnas.1902847116. Epub 2019 Jun 24.

PMID:
31235578
7.

Sequencing and curation strategies for identifying candidate glioblastoma treatments.

Frank MO, Koyama T, Rhrissorrakrai K, Robine N, Utro F, Emde AK, Chen BJ, Arora K, Shah M, Geiger H, Felice V, Dikoglu E, Rahman S, Fang A, Vacic V, Bergmann EA, Vogel JLM, Reeves C, Khaira D, Calabro A, Kim D, Lamendola-Essel MF, Esteves C, Agius P, Stolte C, Boockvar J, Demopoulos A, Placantonakis DG, Golfinos JG, Brennan C, Bruce J, Lassman AB, Canoll P, Grommes C, Daras M, Diamond E, Omuro A, Pentsova E, Orange DE, Harvey SJ, Posner JB, Michelini VV, Jobanputra V, Zody MC, Kelly J, Parida L, Wrzeszczynski KO, Royyuru AK, Darnell RB.

BMC Med Genomics. 2019 Apr 25;12(1):56. doi: 10.1186/s12920-019-0500-0. Erratum in: BMC Med Genomics. 2019 Aug 2;12(1):114.

8.

Author Correction: Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.

Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, Bordbar D, Shan D, Samanamud J, Mahajan A, Filip I, Orenbuch R, Goetz M, Yamaguchi JT, Cloney M, Horbinski C, Lukas RV, Raizer J, Rae AI, Yuan J, Canoll P, Bruce JN, Saenger YM, Sims P, Iwamoto FM, Sonabend AM, Rabadan R.

Nat Med. 2019 Jun;25(6):1022. doi: 10.1038/s41591-019-0449-8.

PMID:
30996326
9.

CD73 Promotes Glioblastoma Pathogenesis and Enhances Its Chemoresistance via A2B Adenosine Receptor Signaling.

Yan A, Joachims ML, Thompson LF, Miller AD, Canoll PD, Bynoe MS.

J Neurosci. 2019 May 29;39(22):4387-4402. doi: 10.1523/JNEUROSCI.1118-18.2019. Epub 2019 Mar 29.

PMID:
30926752
10.

Mismatch repair deficiency in high-grade meningioma: a rare but recurrent event associated with dramatic immune activation and clinical response to PD-1 blockade.

Dunn IF, Du Z, Touat M, Sisti MB, Wen PY, Umeton R, Dubuc AM, Ducar M, Canoll PD, Severson E, Elvin JA, Ramkissoon SH, Lin JR, Cabrera L, Acevedo B, Sorger PK, Ligon KL, Santagata S, Reardon DA.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00190. Epub 2018 Nov 27. No abstract available.

11.

Lesion Dynamics Under Varying Paracrine PDGF Signaling in Brain Tissue.

Massey SC, Hawkins-Daarud A, Gallaher J, Anderson ARA, Canoll P, Swanson KR.

Bull Math Biol. 2019 Jun;81(6):1645-1664. doi: 10.1007/s11538-019-00587-z. Epub 2019 Feb 22.

PMID:
30796683
12.

De novo gene signature identification from single-cell RNA-seq with hierarchical Poisson factorization.

Levitin HM, Yuan J, Cheng YL, Ruiz FJ, Bush EC, Bruce JN, Canoll P, Iavarone A, Lasorella A, Blei DM, Sims PA.

Mol Syst Biol. 2019 Feb 22;15(2):e8557. doi: 10.15252/msb.20188557.

13.

Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.

Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, Bordbar D, Shan D, Samanamud J, Mahajan A, Filip I, Orenbuch R, Goetz M, Yamaguchi JT, Cloney M, Horbinski C, Lukas RV, Raizer J, Rae AI, Yuan J, Canoll P, Bruce JN, Saenger YM, Sims P, Iwamoto FM, Sonabend AM, Rabadan R.

Nat Med. 2019 Mar;25(3):462-469. doi: 10.1038/s41591-019-0349-y. Epub 2019 Feb 11. Erratum in: Nat Med. 2019 Apr 17;:.

PMID:
30742119
14.

Intratumoral heterogeneity of endogenous tumor cell invasive behavior in human glioblastoma.

Parker JJ, Canoll P, Niswander L, Kleinschmidt-DeMasters BK, Foshay K, Waziri A.

Sci Rep. 2018 Dec 20;8(1):18002. doi: 10.1038/s41598-018-36280-9.

15.

Alterations in the Brain Microenvironment in Diffusely Infiltrating Low-Grade Glioma.

Torres D, Canoll P.

Neurosurg Clin N Am. 2019 Jan;30(1):27-34. doi: 10.1016/j.nec.2018.08.001. Epub 2018 Nov 1. Review.

PMID:
30470402
16.

Clinical Reasoning: Transient speech deficits in a patient with history of medulloblastoma.

Schulte JD, Hargus G, Canoll P, Sisti MB, Wang TJC, Lignelli A, Lassman AB.

Neurology. 2018 Sep 18;91(12):e1196-e1201. doi: 10.1212/WNL.0000000000006202. No abstract available. Erratum in: Neurology. 2018 Nov 27;91(22):1031.

PMID:
30224509
17.

Single-cell transcriptome analysis of lineage diversity in high-grade glioma.

Yuan J, Levitin HM, Frattini V, Bush EC, Boyett DM, Samanamud J, Ceccarelli M, Dovas A, Zanazzi G, Canoll P, Bruce JN, Lasorella A, Iavarone A, Sims PA.

Genome Med. 2018 Jul 24;10(1):57. doi: 10.1186/s13073-018-0567-9.

18.

PRMT5-mediated regulation of developmental myelination.

Scaglione A, Patzig J, Liang J, Frawley R, Bok J, Mela A, Yattah C, Zhang J, Teo SX, Zhou T, Chen S, Bernstein E, Canoll P, Guccione E, Casaccia P.

Nat Commun. 2018 Jul 19;9(1):2840. doi: 10.1038/s41467-018-04863-9.

19.

Pineal region glioblastomas display features of diffuse midline and non-midline gliomas.

D'Amico RS, Zanazzi G, Wu P, Canoll P, Bruce JN.

J Neurooncol. 2018 Oct;140(1):63-73. doi: 10.1007/s11060-018-2931-4. Epub 2018 Jul 10.

PMID:
29992434
20.

Combined HDAC and Bromodomain Protein Inhibition Reprograms Tumor Cell Metabolism and Elicits Synthetic Lethality in Glioblastoma.

Zhang Y, Ishida CT, Ishida W, Lo SL, Zhao J, Shu C, Bianchetti E, Kleiner G, Sanchez-Quintero MJ, Quinzii CM, Westhoff MA, Karpel-Massler G, Canoll P, Siegelin MD.

Clin Cancer Res. 2018 Aug 15;24(16):3941-3954. doi: 10.1158/1078-0432.CCR-18-0260. Epub 2018 May 15.

21.

Somatic SLC35A2 variants in the brain are associated with intractable neocortical epilepsy.

Winawer MR, Griffin NG, Samanamud J, Baugh EH, Rathakrishnan D, Ramalingam S, Zagzag D, Schevon CA, Dugan P, Hegde M, Sheth SA, McKhann GM, Doyle WK, Grant GA, Porter BE, Mikati MA, Muh CR, Malone CD, Bergin AMR, Peters JM, McBrian DK, Pack AM, Akman CI, LaCoursiere CM, Keever KM, Madsen JR, Yang E, Lidov HGW, Shain C, Allen AS, Canoll PD, Crino PB, Poduri AH, Heinzen EL.

Ann Neurol. 2018 Jun;83(6):1133-1146. doi: 10.1002/ana.25243. Epub 2018 May 16.

22.

Quantitative assessment of protein activity in orphan tissues and single cells using the metaVIPER algorithm.

Ding H, Douglass EF Jr, Sonabend AM, Mela A, Bose S, Gonzalez C, Canoll PD, Sims PA, Alvarez MJ, Califano A.

Nat Commun. 2018 Apr 16;9(1):1471. doi: 10.1038/s41467-018-03843-3.

23.

Craniotomy and Survival for Primary Central Nervous System Lymphoma.

Rae AI, Mehta A, Cloney M, Kinslow CJ, Wang TJC, Bhagat G, Canoll PD, Zanazzi GJ, Sisti MB, Sheth SA, Connolly ES, McKhann GM, Bruce JN, Iwamoto FM, Sonabend AM.

Neurosurgery. 2019 Apr 1;84(4):935-944. doi: 10.1093/neuros/nyy096.

PMID:
29660011
24.

Comparative dynamics of microglial and glioma cell motility at the infiltrative margin of brain tumours.

Juliano J, Gil O, Hawkins-Daarud A, Noticewala S, Rockne RC, Gallaher J, Massey SC, Sims PA, Anderson ARA, Swanson KR, Canoll P.

J R Soc Interface. 2018 Feb;15(139). pii: 20170582. doi: 10.1098/rsif.2017.0582.

25.

Local Glioma Cells Are Associated with Vascular Dysregulation.

Bowden SG, Gill BJA, Englander ZK, Horenstein CI, Zanazzi G, Chang PD, Samanamud J, Lignelli A, Bruce JN, Canoll P, Grinband J.

AJNR Am J Neuroradiol. 2018 Mar;39(3):507-514. doi: 10.3174/ajnr.A5526. Epub 2018 Jan 25.

26.

Extent of BOLD Vascular Dysregulation Is Greater in Diffuse Gliomas without Isocitrate Dehydrogenase 1 R132H Mutation.

Englander ZK, Horenstein CI, Bowden SG, Chow DS, Otten ML, Lignelli A, Bruce JN, Canoll P, Grinband J.

Radiology. 2018 Jun;287(3):965-972. doi: 10.1148/radiol.2017170790. Epub 2018 Jan 24.

PMID:
29369751
27.

Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastoma.

Smith DR, Wu CC, Saadatmand HJ, Isaacson SR, Cheng SK, Sisti MB, Bruce JN, Sheth SA, Lassman AB, Iwamoto FM, Wang SH, Canoll P, McKhann GM 2nd, Wang TJC.

J Neurooncol. 2018 Apr;137(2):303-311. doi: 10.1007/s11060-017-2718-z. Epub 2017 Dec 20.

PMID:
29264835
28.

Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL.

Karpel-Massler G, Ishida CT, Bianchetti E, Zhang Y, Shu C, Tsujiuchi T, Banu MA, Garcia F, Roth KA, Bruce JN, Canoll P, Siegelin MD.

Nat Commun. 2017 Oct 20;8(1):1067. doi: 10.1038/s41467-017-00984-9.

29.

Letter: Surgical Decision Making From Image-Based Biophysical Modeling of Glioblastoma: Not Ready for Primetime.

Massey SC, Johnston SK, Canoll PD, Bruce JN, Bendok BR, Swanson KR.

Neurosurgery. 2018 Jan 1;82(1):E17-E18. doi: 10.1093/neuros/nyx481. No abstract available.

PMID:
29029349
30.

Simulating PDGF-Driven Glioma Growth and Invasion in an Anatomically Accurate Brain Domain.

Massey SC, Rockne RC, Hawkins-Daarud A, Gallaher J, Anderson ARA, Canoll P, Swanson KR.

Bull Math Biol. 2018 May;80(5):1292-1309. doi: 10.1007/s11538-017-0312-3. Epub 2017 Aug 25.

PMID:
28842831
31.

Quality Assessment of Stereotactic Radiosurgery of a Melanoma Brain Metastases Model Using a Mouselike Phantom and the Small Animal Radiation Research Platform.

Wu CC, Chaudhary KR, Na YH, Welch D, Black PJ, Sonabend AM, Canoll P, Saenger YM, Wang TJC, Wuu CS, Hei TK, Cheng SK.

Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):191-201. doi: 10.1016/j.ijrobp.2017.05.016. Epub 2017 May 19.

32.

Subependymomas Are Low-Grade Heterogeneous Glial Neoplasms Defined by Subventricular Zone Lineage Markers.

D'Amico RS, Praver M, Zanazzi GJ, Englander ZK, Sims JS, Samanamud JL, Ogden AT, McCormick PC, Feldstein NA, McKhann GM 2nd, Sisti MB, Canoll P, Bruce JN.

World Neurosurg. 2017 Nov;107:451-463. doi: 10.1016/j.wneu.2017.08.009. Epub 2017 Aug 10.

PMID:
28804038
33.

Comparing sequencing assays and human-machine analyses in actionable genomics for glioblastoma.

Wrzeszczynski KO, Frank MO, Koyama T, Rhrissorrakrai K, Robine N, Utro F, Emde AK, Chen BJ, Arora K, Shah M, Vacic V, Norel R, Bilal E, Bergmann EA, Moore Vogel JL, Bruce JN, Lassman AB, Canoll P, Grommes C, Harvey S, Parida L, Michelini VV, Zody MC, Jobanputra V, Royyuru AK, Darnell RB.

Neurol Genet. 2017 Jul 11;3(4):e164. doi: 10.1212/NXG.0000000000000164. eCollection 2017 Aug.

34.

Sodium Fluorescein Facilitates Guided Sampling of Diagnostic Tumor Tissue in Nonenhancing Gliomas.

Bowden SG, Neira JA, Gill BJA, Ung TH, Englander ZK, Zanazzi G, Chang PD, Samanamud J, Grinband J, Sheth SA, McKhann GM 2nd, Sisti MB, Canoll P, D'Amico RS, Bruce JN.

Neurosurgery. 2018 May 1;82(5):719-727. doi: 10.1093/neuros/nyx271.

PMID:
28645214
35.

Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses.

Karpel-Massler G, Ishida CT, Bianchetti E, Shu C, Perez-Lorenzo R, Horst B, Banu M, Roth KA, Bruce JN, Canoll P, Altieri DC, Siegelin MD.

Cancer Res. 2017 Jul 1;77(13):3513-3526. doi: 10.1158/0008-5472.CAN-16-3424. Epub 2017 May 18.

36.

Invasiveness is associated with metastasis and decreased survival in hemangiopericytoma of the central nervous system.

Kinslow CJ, Rajpara RS, Wu CC, Bruce SS, Canoll PD, Wang SH, Sonabend AM, Sheth SA, McKhann GM, Sisti MB, Bruce JN, Wang TJC.

J Neurooncol. 2017 Jun;133(2):409-417. doi: 10.1007/s11060-017-2450-8. Epub 2017 Apr 26.

PMID:
28447278
37.

Extent of Resection in Glioma-A Review of the Cutting Edge.

D'Amico RS, Englander ZK, Canoll P, Bruce JN.

World Neurosurg. 2017 Jul;103:538-549. doi: 10.1016/j.wneu.2017.04.041. Epub 2017 Apr 17. Review.

PMID:
28427971
38.

Biphasic Dependence of Glioma Survival and Cell Migration on CD44 Expression Level.

Klank RL, Decker Grunke SA, Bangasser BL, Forster CL, Price MA, Odde TJ, SantaCruz KS, Rosenfeld SS, Canoll P, Turley EA, McCarthy JB, Ohlfest JR, Odde DJ.

Cell Rep. 2017 Apr 18;19(3):668. doi: 10.1016/j.celrep.2017.03.074. No abstract available.

39.

A Multiparametric Model for Mapping Cellularity in Glioblastoma Using Radiographically Localized Biopsies.

Chang PD, Malone HR, Bowden SG, Chow DS, Gill BJA, Ung TH, Samanamud J, Englander ZK, Sonabend AM, Sheth SA, McKhann GM 2nd, Sisti MB, Schwartz LH, Lignelli A, Grinband J, Bruce JN, Canoll P.

AJNR Am J Neuroradiol. 2017 May;38(5):890-898. doi: 10.3174/ajnr.A5112. Epub 2017 Mar 2.

40.

The safety of resection for primary central nervous system lymphoma: a single institution retrospective analysis.

Cloney MB, Sonabend AM, Yun J, Yang J, Iwamoto F, Singh S, Bhagat G, Canoll P, Zanazzi G, Bruce JN, Sisti M, Sheth S, Connolly ES, McKhann G.

J Neurooncol. 2017 Mar;132(1):189-197. doi: 10.1007/s11060-016-2358-8. Epub 2017 Jan 23.

41.

Biphasic Dependence of Glioma Survival and Cell Migration on CD44 Expression Level.

Klank RL, Decker Grunke SA, Bangasser BL, Forster CL, Price MA, Odde TJ, SantaCruz KS, Rosenfeld SS, Canoll P, Turley EA, McCarthy JB, Ohlfest JR, Odde DJ.

Cell Rep. 2017 Jan 3;18(1):23-31. doi: 10.1016/j.celrep.2016.12.024. Erratum in: Cell Rep. 2017 Apr 18;19(3):668.

42.

Aggressive resection at the infiltrative margins of glioblastoma facilitated by intraoperative fluorescein guidance.

Neira JA, Ung TH, Sims JS, Malone HR, Chow DS, Samanamud JL, Zanazzi GJ, Guo X, Bowden SG, Zhao B, Sheth SA, McKhann GM 2nd, Sisti MB, Canoll P, D'Amico RS, Bruce JN.

J Neurosurg. 2017 Jul;127(1):111-122. doi: 10.3171/2016.7.JNS16232. Epub 2016 Oct 7.

PMID:
27715437
43.

Ligation-free ribosome profiling of cell type-specific translation in the brain.

Hornstein N, Torres D, Das Sharma S, Tang G, Canoll P, Sims PA.

Genome Biol. 2016 Jul 5;17(1):149. doi: 10.1186/s13059-016-1005-1.

44.

Diversity and divergence of the glioma-infiltrating T-cell receptor repertoire.

Sims JS, Grinshpun B, Feng Y, Ung TH, Neira JA, Samanamud JL, Canoll P, Shen Y, Sims PA, Bruce JN.

Proc Natl Acad Sci U S A. 2016 Jun 21;113(25):E3529-37. doi: 10.1073/pnas.1601012113. Epub 2016 Jun 3.

45.

Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma.

Lescarbeau RS, Lei L, Bakken KK, Sims PA, Sarkaria JN, Canoll P, White FM.

Mol Cancer Ther. 2016 Jun;15(6):1332-43. doi: 10.1158/1535-7163.MCT-15-0692. Epub 2016 May 17.

46.

Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivo.

Karpel-Massler G, Ramani D, Shu C, Halatsch ME, Westhoff MA, Bruce JN, Canoll P, Siegelin MD.

Oncotarget. 2016 Jun 7;7(23):33512-28. doi: 10.18632/oncotarget.9257.

47.

Olig2-Dependent Reciprocal Shift in PDGF and EGF Receptor Signaling Regulates Tumor Phenotype and Mitotic Growth in Malignant Glioma.

Lu F, Chen Y, Zhao C, Wang H, He D, Xu L, Wang J, He X, Deng Y, Lu EE, Liu X, Verma R, Bu H, Drissi R, Fouladi M, Stemmer-Rachamimov AO, Burns D, Xin M, Rubin JB, Bahassi EM, Canoll P, Holland EC, Lu QR.

Cancer Cell. 2016 May 9;29(5):669-683. doi: 10.1016/j.ccell.2016.03.027.

48.

A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers.

Karpel-Massler G, Horst BA, Shu C, Chau L, Tsujiuchi T, Bruce JN, Canoll P, Greene LA, Angelastro JM, Siegelin MD.

Clin Cancer Res. 2016 Sep 15;22(18):4698-711. doi: 10.1158/1078-0432.CCR-15-2827. Epub 2016 Apr 28.

49.

Glioblastoma Induces Vascular Dysregulation in Nonenhancing Peritumoral Regions in Humans.

Chow DS, Horenstein CI, Canoll P, Lignelli A, Hillman EM, Filippi CG, Grinband J.

AJR Am J Roentgenol. 2016 May;206(5):1073-81. doi: 10.2214/AJR.15.14529. Epub 2016 Mar 23.

50.

Inhibition of deubiquitinases primes glioblastoma cells to apoptosis in vitro and in vivo.

Karpel-Massler G, Banu MA, Shu C, Halatsch ME, Westhoff MA, Bruce JN, Canoll P, Siegelin MD.

Oncotarget. 2016 Mar 15;7(11):12791-805. doi: 10.18632/oncotarget.7302.

Supplemental Content

Loading ...
Support Center